Valuation dashboard for Arcturus Therapeutics Holdings Inc. (ARCT) with P/E N/A, P/B 2.44, EV/EBITDA -3.33 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations.
Analysis Summary
Arcturus Therapeutics Holdings Inc. reported revenue of $67.2M in the most recent fiscal year, growing at a 5-year CAGR of 47.8%.
Trailing-twelve-month margins: gross margin 83.2%, operating margin -433.4%, net margin -391.9%.
At the current price of $15.60, ARCT has negative trailing earnings (P/E not meaningful) and an ROE of -46.54%. Market capitalisation stands at $443M.
Balance sheet quality for ARCT: current ratio of 6.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.44 |
| EV / EBITDA | -3.33 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ARCT | Arcturus Therapeutics Holdings Inc. | $443M | 2.44 | -46.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $15.60 |
| Market Cap | $443M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -46.54% |
| Return on Invested Capital | -52.96% |
| Return on Assets | -41.58% |
| Gross Margin | 83.19% |
| Operating Margin | -433.36% |
| Net Margin | -391.90% |
Related companies: ACHV · AVIR · FHTX · HUMA · IMRX · SGMT · TRDA
Explore sector: Healthcare · Biotechnology
More sections of ARCT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks